TYENNE 162 mg, solution for injection in a pre-filled syringe 4 syringes of 0.9 ml
Active ingredients: Tocilizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection4 syringes of 0.9 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TYENNE 162 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 4 seringues préremplies en verre de 0,9 mL
- Marketing authorisation holder
- FRESENIUS KABI DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 7 Feb 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
62118347CIP73027842CIP133400930278420Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TOCILIZUMABsolution | 162 mg · une seringue préremplie de 0,9 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.